A study published by the scientific journal BMJ Open Diabetes Research & Care shows that an old class of type 2 diabetes drugs can reduce the risk of dementia in patients by 22%.
The drugs are glitazones or TZDs (thiazolidinediones). People age 60 and older receiving thiazolidinedione (TZD) monotherapy for type 2 diabetes had a lower risk of dementia than those receiving metformin monotherapy, according to an observational study.
On the other hand, sulfonylurea monotherapy was associated with a significantly increased risk of dementia, reported Jin Zhu (University of California, Los Angeles, USA) and colleagues.
“These findings may aid in drug selection for elderly patients with type 2 diabetes and high risk of dementia,” the researchers said in a statement.
The result of the study
The study compared these drugs with another antidiabetic drug, metformin.
The researchers worked with patients over 60 who were diagnosed with type 2 diabetes and treated with TZDs, plus volunteers who received only metformin.
Compared with another antidiabetic drug, the drug reduces the likelihood of developing Alzheimer’s and vascular dementia.
After one year of treatment with TZDs alone, patients were 22% less likely to have dementia of any cause compared with those taking metformin alone.
Despite the result, the study is considered observational with no definitive conclusions about cause and effect.
The researchers did not have some information, such as kidney function and genetic factors, for each patient, and the participants were mostly white men.
However, the findings encourage further study on this topic and the development of ways to repurpose type 2 diabetes medication for dementia prevention, prioritizing TZDs.
And that these studies continue so that a cure for Alzheimer’s and other types of dementia will soon be found.
According to MedWireNews